Kornimate/medical-research-clean huggingface dataset:
proprioceptive neuromuscular facilitation in the flexibility and strength of flexor muscles and hamstrings

Conditions: Proprioceptive Disorders

Summary: introduction: the loss of normal values of rom due to the lack of flexibility and strength in the hip flexors, quadriceps and hamstrings in soccer players can cause a loss of mobility of the hip and knee joint. proprioceptive neuromuscular facilitation is an active-assisted stretching technique used to improve flexibility and therefore the ranges of joint mobility. aim. to assess the effectiveness of an intervention by proprioceptive neuromuscular facilitation in the improvement of flexibility and strength in the hamstring, hip flexor and quadriceps musculature compared to conventional stretches in football players. study design. randomized, multicentric, single-blind clinical study. methods. the 30 players will be randomly assigned to the study groups: experimental (proprioceptive neuromuscular facilitation and static stretches) and control (static stretches). the treatment will last 6 weeks, with two sessions a week of 5 minutes each. the study variables will be the range of hip mobility (using goniometry), hamstring flexibility (using the epr test, inclinometer) and the strength of hip flexors, quadriceps and hamstrings (through the rm test). a descriptive statistical analysis will be carried out calculating the main statistical characteristics and after calculating the normality of the sample (test kolmogorov- smirnov), the differences between evaluations in each group (t-student test) and the intra- and intersubject effect will be calculated (anova of repeated measures). expected results. improved hip mobility, hamstring flexibility and strength in hip flexors, quadriceps and hamstrings muscles.


Eligibility criteria:
inclusion criteria: * volleyball players * male * from 18 to 30 years old * federated in the royal federation of football of the community of madrid * not had any musculoskeletal injuries in the last 3 months. exclusion criteria: * impossibility, for work or academic reasons, to comply with the requirements of the study (interventions and evaluations); * under pharmacological treatment * who are exercising a physiotherapy treatment parallel to the development of the study * not sign the informed consent document.

Keywords: proprioceptive neuromuscular facilitation range of motion stretching muscle strength randomized clinical trial
aliskiren or amlodipine in hypertensive hemodialysed patients

Conditions: Hypertension; Dialysis

Summary: hypertensive haemodialysis patients are at high risk for cardiovascular events. this study was undertaken to ascertain whether aliskiren, a direct renin inhibitor, compared with amlodipine, a calcium channel blocker, reduces mortality and cardiovascular events in these high-risk patients.


Eligibility criteria:
inclusion criteria: * hemodialysed patients * predialytic blood pressure greater or equal to 140/90 mmhg exclusion criteria: * history of heart failure * history of ischemic heart disease * severe aortic stenosis * known allergy to aliskiren or amlodipine * severe disorders of liver function

Keywords: hypertension dialysis aliskiren amlodipine outcome
clinical applicability of pcasl as a substitute for fdg-pet in mci and scd patients

Conditions: Mild Cognitive Impairment; Subjective Cognitive Decline

Summary: the goal of this observational study is to compare cerebral perfusion patterns with pseudo-continuous arterial spin labeling (pcasl) and brain metabolism patterns with fluorodeoxyglucose-position emission tomography (fdg-pet) in patients with mild cognitive impairment (mci) and subjective cognitive decline (scd). the main questions it aims to answer are: * do pcasl sequences identify hypoperfusion patterns that correlate well with fdg-pet hypometabolic patterns? * are there differences in this correlation in terms of cerebrospinal fluid (csf) profiles? * can hypoperfusion patterns in pcasl predict conversion to dementia? participants will undergo brain 3 tesla magnetic resonance imaging (mri), fdg-pet, lumbal puncture and blood collection to analyze amyloid beta and tau, yearly detailed neuropsychological tests for three years.


Eligibility criteria:
inclusion criteria: * patients with mild cognitive impairment or subjective cognitive decline according to established criteria * clinical dementia rating scale of 0 or 0.5 * signed informed consent before study entry exclusion criteria: * contraindication to brain mri, fdg-pet or lumbar puncture * secondary causes of cognitive decline * known major neurological or psychiatric comorbidities * history of substance or alcohol abuse * known causes of cerebral brain perfusion alterations * enrollment in anti-amyloid or anti-tau drugs trials

Keywords: pseudo-continuous arterial spin labeling fluorodeoxyglucose positron emission tomography mild cognitive impairment biomarkers subjective cognitive decline
mk0633 single dose study in japanese asthmatic children aged 12 to less than 16 years (0633-028)

Conditions: Asthma

Summary: this study evaluates the safety, tolerability and pharmacokinetics (pk) of mk0633 in adolescent mild-to-moderate japanese asthma patients to permit further clinical investigation


Eligibility criteria:
inclusion criteria: * patient is judged to be in good health, other than having mild to moderate asthma, based on medical history, physical examination, vital signs, and laboratory safety tests * patient has no clinically significant abnormality on electrocardiogram (ecg) performed at the prestudy (screening) visit and/or prior to administration of the initial dose of study drug * patient has at least 1 year of mild-to-moderate asthma * patient has been a nonsmoker for at least 6 months * patients of childbearing potential must agree to use a medically acceptable method of contraception during the study * patients must be able to swallow tablets exclusion criteria: * patient has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, other than asthma, or genitourinary abnormalities or diseases * patient has required a visit to a hospital or emergency room due to an asthma exacerbation within 3 months of the prestudy visit * patient has unresolved signs and symptoms of an upper respiratory tract infection (uri) or has had had an upper respiratory tract infection within 3 weeks prior to the prestudy visit * patient has a history of stroke, chronic seizures, or major neurological disorder * patient has a history of neoplastic disease * use of theophylline, anti-allergic compounds (except for nasal drop and eye-drop omalizumab, zileuton, oral corticosteroid, and oral beta agonists (including patch) are excluded \~ 2 weeks prior to administration of study drug and throughout the study 7)patient consumes alcoholic beverages
effects of two strength exercise programs on upper limb functionality in breast cancer

Conditions: Breast Cancer Survivor; Breast Cancer; Breast Cancer Patients; Breast Cancer - Female

Summary: the goal of this experimental study is to evaluate the effect of a therapeutic exercise program based on upper limb plyometric exercises in breast cancer patients and breast cancer survivors to determine changes in upper limb functionality. the main question it aims to answer is: does upper limb plyometric strength exercise improve upper limb dysfunctions in breast cancer patients and survivors? the researchers will compare the effects of plyometric exercise with the effects of strength training exercise to determine whether plyometric exercise improves shoulder dysfunctions in breast cancer patients and survivors. participants from the pontevedra group will undergo the intervention using plyometric exercise (experimental group), while those from the vigo group will perform strength training exercise (control group). they will complete two sessions per week for six weeks. outcome variables related to upper limb functionality will be assessed at baseline and after the intervention.


Eligibility criteria:
inclusion criteria: * pathological diagnosis of breast cancer. * patients who have undergone a mastectomy, including unilateral, total breast, or breast-conserving surgery. * postoperative chemotherapy or radiotherapy as required. * no other malignant tumors in the last 5 years. * absence of contraindications related to physiotherapy or physical exercise. * willingness to participate in the study and sign the informed consent form. exclusion criteria: * metastasis to other organs and tissues (liver, kidney, lung, brain, etc.) that prevent participation in the exercise program. * underlying heart disease, cerebrovascular disease, or mental illness that impairs proper execution of the exercise program. * pre-existing shoulder pathology before surgery. * inability to understand the plyometric exercise program.

Keywords: breast cancer plyometric exercise upper limb strength training exercise recovery of function clinical trial
comparison of ketamine and etomidate during rapid sequence intubation in trauma patients

Conditions: Trauma; Shock, Traumatic

Summary: in trauma patients with high shock index, the investigators compare the effects on hemodynamics between ketamine and etomidate.

in trauma patients, rapid sequence intubation is recommended. the drug of choice, however, has been debated. one cohort comparative study showed ketamine had benefit in hemodynamics compared to etomidate in trauma patients. one observational study showed in high shock index patients, ketamine showed maintain systolic blood pressure. and other retrospective showed less clinical hypotension was less in ketamine. however there is no randomized controlled study comparing ketamine and etomidate in trauma patients. the purpose of this study is comparing the effects of hemodynamics between ketamine and etomidate in high shock index trauma patients.

Eligibility criteria:
inclusion criteria: * age 19\~70 * shock index ≥ 0.9 * patients who need intubation regarding to ajou trauma center protocol exclusion criteria: * during cpr * cpr before hospital arrival * severe head trauma * steroid intake history

Keywords: etomidate ketamine rapid sequence intubation trauma hemodynamics
low-dose radiotherapy in inhl

Conditions: Indolent Lymphoma; Low-dose Radiotherapy

Summary: the current study is a phase ii multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 gy\*4f) in indolent lymphoma.


Eligibility criteria:
inclusion criteria: * pathology proved inhl * ecog ps ≤3 * signed informed consent exclusion criteria: * history of radiotherapy at the same site * primary malignant lymphoma of the gastrointestinal tract * ctv (clinical target volume)\>500ml * others that researchers consider inappropriate

Keywords: indolent lymphoma low-dose radiotherapy
biomarker expression in samples from young patients with anaplastic large cell lymphoma

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.

objectives: * to determine the expression of immunoregulatory proteins including cd4, foxp3 and cd276 in anaplastic large cell lymphoma (alcl). * to correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (alk) autoantibodies in patient of anhl0131. outline: archived tissue microarray samples are analyzed by mass spectrometry and validated by western blotting, flow cytometry, and ihc.

Eligibility criteria:
disease characteristics: * diagnosis of anaplastic large cell lymphoma * tissue microarray samples available from the cooperative human tissue network (chtn) patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood anaplastic large cell lymphoma
oxandrolone rotator cuff trial

Conditions: Rotator Cuff Tear

Summary: this study is about healing after a rotator cuff tear repair procedure. we hope to learn if a biologic medication: oxandrolone, a synthetic derivative of the human hormone testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks following rotator cuff repair, is effective in aiding in the healing process and restoring muscle mass.


Eligibility criteria:
inclusion criteria: * scheduled for rotator cuff repair * failed nonoperative management of chronic, full thickness rotator cuff tears * full thickness rotator cuff tear confirmed on mri exclusion criteria: * patients with prior shoulder surgery or prior rotator cuff repair * tears larger than 5 cm * significant glenohumeral arthritis (hamada grade 2 or higher) * untreated diabetes mellitus * pituitary tumor * rheumatoid arthritis * uncontrolled hypertension * congestive heart failure * myocardial infarction within the past 6 months * end-stage renal disease * liver enzymes two times the normal value * deep vein thrombosis (dvt) within the past 6 months * disorder of the coagulation system * currently taking anticoagulation * claustrophobia * prior or current use of anabolic steroids * chromosomal disorders * prostate cancer * breast cancer * hypercalcemia * medications that interfere with testosterone production or function, including but not limited to 5 alpha-reductase inhibitors * pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 weeks after the last dose of study treatment * any other condition or treatment interfering with completion of the trial

Keywords: rotator cuff tear rotator cuff anabolic steroid testosterone oxandrolone
a study to evaluate the efficacy and safety of hr18042 tablets for postoperative analgesia after impacted teeth removal surgery.

Conditions: Pain

Summary: this is a multicenter, randomized, double-blind, dose finding, parallel controlled with active drug and placebo, phase ii clinical trial, and the purpose of the study is to evaluate the efficacy and safety of hr18042 tablets for postoperative analgesia after impacted teeth removal surgery.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. scheduled to remove the impacted tooth. 3. any nrs score reaches the inclusion criteria within 4 hours after the surgery. 4. willing to comply with the study procedures and requirements. 5. willing and able to provide written informed consent for this study. exclusion criteria: 1. subjects who have used other drugs that have the analgesic effect. 2. subjects who have used any drug that affect the efficacy and safety of study drug. 3. subjects who have infection or other complications on the planned oral surgical site. 4. subjects with hypertension or hypotension during screening period. 5. subjects with severe cardiovascular and cerebrovascular diseases. 6. subjects with severe gastrointestinal disease. 7. subjects with respiratory diseases. 8. subjects with a history of seizure, or drug or alcohol abuse. 9. subjects with significant abnormal electrocardiogram result. 10. subjects with significant abnormal laboratory value. 11. subject who were allergic to the study drug and ingredients. 12. pregnancy, lactation or having recent pregnant plan. 13. subjects who participated in other clinical research study 30 days before entering this study. 14. other conditions unsuitable for participation in the study.
muscle stimulation in advanced idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the aims of this study are to determine whether neuromuscular stimulation (nmes) of the quadriceps muscle is acceptable to patients with idiopathic pulmonary fibrosis (ipf) and staff and whether it can impact clinical and healthcare resource usage outcomes. .

patients with ipf who consent to participate in the study will be allocated by chance to use 'active' or 'sham/placebo' nmes for six weeks. patients will also complete a home exercise programme and receive advice on how to manage breathlessness. clinical outcomes and trial flow after this six week programme and six weeks after patients have stopped using nmes will be assessed. after this point, healthcare resource use during the study period will be evaluated and interviews involving participants, their carers, and staff about their experiences of the study and using or delivering nmes will be conducted.

Eligibility criteria:
inclusion criteria: * diagnosis of ipf according to international standards. * severe respiratory disability / breathlessness (medical research council dyspnoea score ≥3). * able to provide written informed consent. * declined or failed to complete a supervised centre-based pulmonary rehabilitation (pr) programme * quadriceps maximum voluntary contraction \<80% predicted. exclusion criteria: * cardiac pacemaker. * co-existing neurological condition. * change in medication or exacerbation requiring admission in preceding four weeks. * current regular exerciser (structured supervised training ≥3 times per week within last month). * people who have completed pr in the previous six months.

Keywords: neuromuscular electrical stimulation
postoperative adjuvant chemotherapy in early-stage cervical cancer that not meet criteria of adjuvant therapeutic according to nccn guideline

Conditions: Uterine Cervical Neoplasms; Cervical Cancer

Summary: this is a prospective, phase 3 randomized controlled clinical trial. cervical cancer patients who undergo radical surgery but do not meet criteria of adjuvant therapy according to nccn guideline are enrolled to receive adjuvant chemotherapy. the primary endpoint was disease-free survival (dfs) rate at 3 year. the secondary endpoints were 5-year dfs, overall survival (os) and safety.


Eligibility criteria:
inclusion criteria: 1. patients with 2018 figo staged ib1, ib2, iia1 cervical cancer. 2. the initial treatment was radical hysterectomy + pelvic lymphadenectomy by laparotomy or laparoscopy with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator. 3. postoperative pathological diagnosis was cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma. 4. assessment of risk factors not meeting sedlis criteria （nccn guideline），but having one of following factors ：（1）deep stromal infiltration（≥2/3 layer）；（2）histopathological differentiation grade g2 \~ g3；（3）lymph-vascular space invasion ；（4）adenocarcinoma or adenosquamous cell carcinoma；（5）tumor size ≥2cm. 5. age：18-70 years old. 6. wbc≥3.5\*10\^9/l, neu≥1.5\*10\^9/l, platelet≥80×10\^9 /l; ast and alt ≤1.5 times normal upper limit; total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value. 7. eastern cooperative oncology group score 0-1. 8. well-compliance and willing to keep in touch. 9. willing to participate in this study, and sign the informed consent. exclusion criteria: 1. postoperative pathology has high-risk factors（lymph node metastasis, parametrial infiltration or positive surgical margin）or meets sedlis criteria. 2. participate in other clinical trials at the same time. 3. comorbidity including but not limited to: heart diseases (grade iii-iv cardiac insufficiency (nyha standard); central nervous system diseases or nonfunctional behavior; hematological system diseases; liver or kidney malformation or history of surgery. 4. persons without disposing capacity. 5. drug and/or alcohol abuse. 6. unable or unwilling to sign informed consents. 7. not eligible for the study judged by researchers.
accuracy of pulse oximeters with profound hypoxia at rest (niho16)

Conditions: Hypoxia

Summary: the aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. study will be used with patients at rest.

this study is intended to evaluate performance of a new design pulse oximeter (test device) manufactured by nihon kohden corporation sufficiently to support performance claims for an fda 510k submission or iso technical file. specifically, spo2 and pulse rate accuracy will be assessed for a nihon kohden olv-4202 pulse oximeter with adult patients under a controlled setting of varying levels of inhaled oxygen concentration levels for patients at rest.

Eligibility criteria:
inclusion criteria: * both male and female subjects who can give written informed consent * healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile * meeting the demographic requirements exclusion criteria: * age below 18 or over 50 * pregnant women * significant arrhythmia * blood pressure above 150 systolic or 90 diastolic * carboxyhemoglobin levels over 3% * subjects whom the investigator consider ineligible for the study
cardiometabolic disease and pulmonary hypertension

Conditions: Obesity

Summary: this study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. metformin is approved by the u.s. food and drug administration (fda) to treat diabetes, but metformin is not approved by the fda to treat pulmonary hypertension. this study will examine whether metformin will improve the high pressure inside lung blood vessels in people who are obese. the study will help understand the effect of metformin on pressures inside lung blood vessels.

obesity can predispose people to develop high pressures inside their lung blood vessels, a condition called pulmonary hypertension, pulmonary hypertension in turn, can lead to shortness of breath and other health complications such as heart failure. in this study, we seek to identify individuals at risk for the development of high pressures inside lung vessels based on bmi and dyspnea grade 1. participants will be screened by echocardiography to estimate pulmonary pressures. potential participants will undergo invasive cardiopulmonary exercise testing with hemodynamic monitoring, in order to identify individuals with abnormal pulmonary vascular function either at rest or during exercise. patients who have undergone clinically-indicated cardiopulmonary exercise testing and meet inclusion/exclusion criteria will also be recruited. those with abnormal pulmonary vascular function will be randomized to receive metformin or placebo for a total of 3 months under an ind exemption. the primary outcomes include the effect on pulmonary vascular function at rest and during exercise. secondary outcomes include change in pulmonary artery endothelial cell phenotypes.

Eligibility criteria:
inclusion criteria: * age 30-80 years * history of obesity and current bmi ≥ 25 kg/ m2 for study volunteers or bmi ≥ 25 kg/ m2 for those with clinically indicated cpet or known hfpef * history of dyspnea (grade 1 or more) * able to provide informed consent and willing to comply with study exclusion criteria: * history of diabetes mellitus * history of primary pulmonary arterial hypertension * history of moderate to severe copd * history of severe obstructive sleep apnea * history of renal disease (egfr\< 45 ml/min/1.732) * history of severe liver disease * history of cardiovascular disease (recent heart attack or stroke) except known hfpef * history of blood clot in lung * history of splenectomy * history of active cancer * platelets count of \< 75,000 * international normalized ration (inr) of \> 1.5 * history of recent anemia (hb \< 9g/dl) * current use of metformin * prior lvef \< 50% on echocardiogram * indication of severe valvular disease on echo * pregnant or planning to become pregnant in next 4 months * history of hiv infection

Keywords: pulmonary hypertension bmi echocardiography cpet 6-minute walk test cardio metabolic disease